4.6 Article

Fhit Deficiency-Induced Global Genome Instability Promotes Mutation and Clonal Expansion

期刊

PLOS ONE
卷 8, 期 11, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0080730

关键词

-

资金

  1. National Institutes of Health (United States Public Health Service) [CA120516, CA132453, CA115965, F31CA157150, T32GM068412]
  2. Ohio State University Wexner Medical Center

向作者/读者索取更多资源

Loss of Fhit expression, encoded at chromosome fragile site FRA3B, leads to increased replication stress, genome instability and accumulation of genetic alterations. We have proposed that Fhit is a genome 'caretaker' whose loss initiates genome instability in preneoplastic lesions. We have characterized allele copy number alterations and expression changes observed in Fhit-deficient cells in conjunction with alterations in cellular proliferation and exome mutations, using cells from mouse embryo fibroblasts (MEFs), mouse kidney, early and late after establishment in culture, and in response to carcinogen treatment. Fhit(-/-) MEFs escape senescence to become immortal more rapidly than Fhit(+/+) MEFs; -/- MEFs and kidney cultures show allele losses and gains, while +/+ derived cells show few genomic alterations. Striking alterations in expression of p53, p21, Mcl1 and active caspase 3 occurred in mouse kidney -/- cells during progressive tissue culture passage. To define genomic changes associated with preneoplastic changes in vivo, exome DNAs were sequenced for +/+ and -/- liver tissue after treatment of mice with the carcinogen, 7,12-dimethylbenz[a] anthracene, and for +/+ and -/- kidney cells treated in vitro with this carcinogen. The -/- exome DNAs, in comparison with +/+ DNA, showed small insertions, deletions and point mutations in more genes, some likely related to preneoplastic changes. Thus, Fhit loss provides a 'mutator' phenotype, a cellular environment in which mild genome instability permits clonal expansion, through proliferative advantage and escape from apoptosis, in response to pressures to survive.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C

Hisamitsu Miyaaki, Satoshi Miuma, Naota Taura, Hidetaka Shibata, Akihiko Soyama, Masaaki Hidaka, Mitsuhisa Takatsuki, Susumu Eguchi, Kazuhiko Nakao

HEPATOLOGY RESEARCH (2018)

Article Medicine, Research & Experimental

Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan

Satoshi Miuma, Masaaki Hidaka, Mitsuhisa Takatsuki, Koji Natsuda, Akihiko Soyama, Hisamitsu Miyaaki, Yasuko Kanda, Yoko Tamada, Hidetaka Shibata, Eisuke Ozawa, Naota Taura, Susumu Eguchi, Kazuhiko Nakao

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2018)

Article Gastroenterology & Hepatology

Utilization and efficacy of elbasvir/grazoprevir for treating hepatitis C virus infection after liver transplantation

Satoshi Miuma, Hisamitsu Miyaaki, Akihiko Soyama, Masaaki Hidaka, Mitsuhisa Takatsuki, Hidetaka Shibata, Naota Taura, Susumu Eguchi, Kazuhiko Nakao

HEPATOLOGY RESEARCH (2018)

Review Oncology

Mechanisms shaping the mutational landscape of the FRA3B/FHIT-deficient cancer genome

Joshua C. Saldivar, Dongju Park

GENES CHROMOSOMES & CANCER (2019)

Article Gastroenterology & Hepatology

Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis

Masafumi Haraguchi, Satoshi Miuma, Hiroshi Masumoto, Tatsuki Ichikawa, Yasuko Kanda, Ryu Sasaki, Masanori Fukushima, Hisamitsu Miyaaki, Naota Taura, Kazuhiko Nakao

HEPATOLOGY INTERNATIONAL (2019)

Article Gastroenterology & Hepatology

Deep sequence analysis of NS5A resistance-associated substitution changes in patients reinfected with the hepatitis C virus after liver transplantation

Shinobu Yamamichi, Satoshi Miuma, Takayuki Wada, Hiroshi Masumoto, Yasuko Kanda, Hidetaka Shibata, Hisamitsu Miyaaki, Naota Taura, Tatsuki Ichikawa, Taro Yamamoto, Kazuhiko Nakao

JOURNAL OF VIRAL HEPATITIS (2020)

Editorial Material Cell Biology

Cohesin Is Out for Stalled Replication Fork Restart

Sebnem Ece Eksi, Joshua C. Saldivar

DEVELOPMENTAL CELL (2020)

Article Gastroenterology & Hepatology

Geranylgeranylacetone decreases the production of hepatitis B virus-related antigen by comprehensive downregulation of mRNA transcription activity

Masafumi Haraguchi, Satoshi Miuma, Kazuo Yamamoto, Yasuhiko Nakao, Tatsuki Ichikawa, Yasuko Kanda, Ryu Sasaki, Masanori Fukushima, Yuko Akazawa, Hisamitsu Miyaaki, Kazuhiko Nakao

Summary: The study found that geranylgeranylacetone (GGA) can reduce HBV protein levels by comprehensively downregulating HBV promoter and enhancer activity. GGA treatment also leads to changes in HBV-related mRNA and endoplasmic reticulum stress marker expression levels, which may enhance the anti-HBV effects.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

News Item Biochemistry & Molecular Biology

Restraining CDK1-cyclin B activation: PP2A on the cUSP(7)

Marilynn Chow-Castro, Shandee D. Dixon, Joshua C. Saldivar

Summary: USP7 inhibitors are gaining traction as a therapeutic strategy for stabilizing p53, but they also come with unexpected p53-independent toxicity through an unknown mechanism. New research shows that inhibition of USP7 leads to the redistribution of PP2A from the cytoplasm to the nucleus, and an increase in deleterious CDK1-dependent phosphorylation throughout the cell cycle, revealing a new regulatory mechanism for maintaining genomic integrity in S-phase cells progressing towards mitosis.

EMBO JOURNAL (2021)

Article Gastroenterology & Hepatology

Bile extracellular vesicles from end-stage liver disease patients show altered microRNA content

Suguru Nakashiki, Satoshi Miuma, Hiroyuki Mishima, Hiroshi Masumoto, Masaaki Hidaka, Akihiko Soyama, Yasuko Kanda, Masanori Fukushima, Masafumi Haraguchi, Ryu Sasaki, Hisamitsu Miyaaki, Tatsuki Ichikawa, Mitsuhisa Takatsuki, Susumu Eguchi, Koh-ichiro Yoshiura, Kazuhiko Nakao

Summary: EVs, particularly bile EVs, show potential as novel biomarkers for liver diseases, with higher concentrations observed in recipients with liver failure, particularly those with hepatocellular carcinoma. The miRNA content in bile EVs increases in the ESLD state, and these miRNA levels are not correlated with those in serum EVs, indicating their promise as diagnostic tools.

HEPATOLOGY INTERNATIONAL (2021)

Article Medicine, General & Internal

Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells

Hillary H. Le, Suleyman S. Cinaroglu, Elise C. Manalo, Aysegul Ors, Michelle M. Gomes, Burcin Duan Sahbaz, Karla Bonic, Carlos A. Origel Marmolejo, Arnaud Quentel, Justin S. Plaut, Taryn E. Kawashima, E. Sila Ozdemir, Sanjay Malhotra, Yavuz Ahiska, Ugur Sezerman, Gunseli Bayram Akcapinar, Joshua C. Saldivar, Emel Timucin, Jared M. Fischer

Summary: The study demonstrates that newly developed peptides can target and eliminate senescent cancer cells, reducing cancer recurrence and improving survival rates. These peptides exhibit significant apoptosis and survival advantages in vivo, with minimal toxicity in older mice.

EBIOMEDICINE (2021)

Article Biochemistry & Molecular Biology

Estrogen regulates divergent transcriptional and epigenetic cell states in breast cancer

Aysegul Ors, Alex Daniel Chitsazan, Aaron Reid Doe, Ryan M. Mulqueen, Cigdem Ak, Yahong Wen, Syber Haverlack, Mithila Handu, Spandana Naldiga, Joshua C. Saldivar, Hisham Mohammed

Summary: This study systematically tracked the response of breast cancer cells to estrogen at a single-cell level and uncovered the non-uniform nature of gene expression response. Different cell groups were found to express distinct transcriptional networks and have different chromatin accessibility states.

NUCLEIC ACIDS RESEARCH (2022)

Article Surgery

Regular protocol liver biopsy is useful to adjust immunosuppressant dose after adult liver transplantation

Shohei Narita, Satoshi Miuma, Sadayuki Okudaira, Yoshito Koga, Masanori Fukushima, Ryu Sasaki, Masafumi Haraguchi, Akihiko Soyama, Masaaki Hidaka, Hisamitsu Miyaaki, Mitsuru Futakuchi, Kazuhiro Nagai, Tatsuki Ichikawa, Susumu Eguchi, Kazuhiko Nakao

Summary: This study retrospectively evaluated the usefulness of late protocol liver biopsy (PLB) after adult liver transplantation. The results showed that PLB is valuable for detecting subclinical rejection and allowing for appropriate immunosuppressive dose adjustment.

CLINICAL TRANSPLANTATION (2023)

Article Oncology

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma

Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Kotaro Fukubayashi, Motohiko Tanaka, Yasuhito Tanaka

Summary: This study aimed to evaluate the impact of therapeutic modifications of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (uHCC). Patients with therapeutic modifications other than discontinuation of both drugs had favorable overall survival and time to progression, while those with discontinuation of both drugs had unfavorable outcomes. Modified liver function and immune-related adverse events increased the risk of discontinuation without other therapeutic modifications. Avoiding discontinuation without other therapeutic modifications may be the optimal management for uHCC.

CANCERS (2023)

Article Medicine, Research & Experimental

Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models

Manal Mehibel, Yu Xu, Caiyun G. Li, Eui Jung Moon, Kaushik N. Thakkar, Anh N. Diep, Ryan K. Kim, Joshua D. Bloomstein, Yiren Xiao, Julien Bacal, Joshua C. Saldivar, Quynh-Thu Le, Karlene A. Cimprich, Erinn B. Rankin, Amato J. Giaccia

Summary: Hypoxia, a characteristic of the tumor microenvironment, has been shown to confer resistance to traditional chemotherapy but can synergize with PARP inhibitors under severe hypoxia. Moderate hypoxia, however, promotes resistance to PARP inhibitors. Selective elimination of hypoxic tumor cells enhances the efficacy of PARP inhibitor therapy without increasing normal tissue toxicity.

JOURNAL OF CLINICAL INVESTIGATION (2021)

暂无数据